Compare Tenaris S.A. American Depositary Shares (TS) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tenaris S.A. American Depositary Shares vs GeneDx Holdings Corp — how do they compare? Tenaris S.A. American Depositary Shares trades at $57.21 (market cap $29.31B), while GeneDx Holdings Corp trades at $68.8 (market cap $1.94B). The key difference: Tenaris S.A. American Depositary Shares is far larger — about 15.1× GeneDx Holdings Corp's market cap, and Tenaris S.A. American Depositary Shares pays a 4.07% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tenaris S.A. American Depositary Shares for 0 Days and GeneDx Holdings Corp for 20 Days on average.
| TS | WGS | |
|---|---|---|
Market Cap | $29.31B | $1.94B |
Volume | 802,043 | 524,385 |
Sector | Energy | Health |
52-Week High | $64.02 | $167.51 |
52-Week Low | $34.28 | $34.51 |
Typical Hold Time | 0 Days | 20 Days |
Enterprise Value | $26.97B | $1.97B |
Dividend Yield | 4.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tenaris (TS) trades at $58.54, up 0.84% with neutral technical signals and strong fundamental metrics including a P/E of 15.65 and net income margin of 15.88%. Recent earnings beats and a $1.18 dividend support investor confidence, though cash flow trends show modest net outflows. The stock faces near-term headwinds from shipment delays and margin compression as noted in recent analyst reports.
The outlook remains balanced with analyst consensus favoring Buy (57.69%) and a $66.67 price target suggesting 14% upside. Key risks include cyclical energy sector exposure and operational disruptions, but solid profitability and valuation support make TS attractive for dividend and value investors seeking energy sector exposure.
GeneDx (WGS) trades at $64.96, up 1.79% today, showing mixed signals with bearish technical indicators but strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating expectations with record testing volumes, though profitability remains challenged with negative net margins. Recent news highlights product innovations and leadership recognition, while institutional interest grows with Dimensional Fund Advisors increasing its position by 143.4% in Q1 2026.
The stock presents a high-risk opportunity with 91% analyst buy ratings and an $81 consensus target offering 25% upside. However, significant fundamental challenges include negative profitability, high valuation multiples, and cash flow volatility. Investors should weigh strong growth potential in genomic testing against execution risks and competitive pressures in the healthcare technology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tenaris S.A. American Depositary Shares
Tenaris S.A. manufactures seamless and welded steel pipe products, including casing, tubing, and line pipe, for the oil and gas industry and certain industrial applications. The company operates an integrated production network across 17 countries and offers Rig Direct, its integrated supply-chain service for oilfield customers.
Read more on TS →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
